Depatuxizumab mafodotin
Overview[edit]
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. It combines a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) with a potent cytotoxic agent, mafodotin, which is a derivative of the microtubule-disrupting agent monomethyl auristatin F (MMAF).
Mechanism of Action[edit]
Depatuxizumab mafodotin works by specifically targeting and binding to EGFR, which is overexpressed in various tumors. Upon binding, the ADC is internalized by the cancer cell, where the cytotoxic agent mafodotin is released. This agent disrupts the microtubule network within the cell, leading to cell cycle arrest and apoptosis.
Development and Clinical Trials[edit]
Depatuxizumab mafodotin has been evaluated in several clinical trials for its efficacy and safety in treating glioblastoma and other EGFR-expressing tumors. The results have shown promise, particularly in patients with recurrent glioblastoma.
Side Effects[edit]
The administration of depatuxizumab mafodotin can lead to various side effects, including ocular toxicity, fatigue, and hematologic toxicity. These side effects are primarily due to the action of the cytotoxic agent mafodotin.
